Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07232121Phase 1Recruiting

A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults

Role: lead

NCT04423029Phase 1Completed

A Study of DF6002 Alone and in Combination With Nivolumab

Role: lead

NCT04143711Phase 1Completed

Study of DF1001 in Patients With Advanced Solid Tumors

Role: lead

NCT06108479Phase 1Completed

Study of DF6215 in Patients With Advanced Solid Tumors

Role: lead

NCT05597839Phase 1Completed

Study of DF9001 in Patients With Advanced Solid Tumors

Role: lead

All 5 trials loaded